Introducing Quine: An AI research system designed for the complexity of biology
Microsoft Nicolo Fusi, Jonathan M. Carlson
Microsoft Research built Quine, an AI system for biology research. It’s already helping rank cancer compounds in wet-lab tests, but it’s still research-only.
Based on reporting by Microsoft, Nicolo Fusi, Jonathan M. Carlson — read the original for the full story.
Summary, retelling and take written by AI under human oversight; images are AI-generated illustrations. How we work · Report an error
Microsoft Research has introduced Quine, an experimental system built to handle biology as a messy, connected problem rather than a neat set of separate tasks. The company says it combines a multimodal world model of biology with a harness that links models, scientific tools, literature, wet-lab work, and the researchers using them.
The pitch is straightforward: biology moves across scales, from sequence to structure to cells to tissues, and models that stay trapped in one slice of that picture miss too much. Quine tries to learn those pieces together. Microsoft says that joint training lets evidence from one modality inform predictions in another, instead of forcing a handful of specialist models to sit side by side like strangers at a conference table.
The most concrete test so far came in pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. Working with researchers at the Broad Institute of MIT and Harvard, Microsoft used Quine to rank thousands of compounds for their ability to push tumor cells between therapeutically relevant states. In tests focused on the classical-to-basal transition, the top-ranked compounds produced the biggest intended shifts across several assays. The company says the full loop, from narrowing the search to choosing candidates for lab validation, took one weekend.
And Quine didn’t just confirm what the team already suspected. Some of the strongest effects came from compounds with unexpected mechanisms of action, and the experiments also pointed to a third cell phenotype rather than only a simple classical-basal split. Microsoft says that richer picture is feeding back into the system through newly integrated RNA data and state-transition tasks.
For now, access is narrow. The Quine Fellows program will put the system in the hands of a cohort of scientists, and Microsoft says the technology is for research only, not clinical or medical use. As it matures, the company expects to widen access through products like Microsoft Discovery.
My take — AI-written commentary, not fact-checked reporting
This is the rare AI-for-science story that sounds less like a demo and more like a lab workflow. The real tell is that Microsoft is talking about one weekend of narrowing, ranking, and validation, not flashy benchmark theater. Biology has been humbling model builders for years; Quine’s bet is that useful imperfection beats polished irrelevance.
Read more about this at: Microsoft
